STAT+: Early data suggest monthly hemophilia drug could contend with gene therapy
Centessa, a biotech company that raised more than $300 million in an IPO earlier this year, has an early-stage treatment for hemophilia that might compete with the gene therapies nearing the market.
The company’s drug, a monthly treatment injected under the skin, significantly reduced the rate of bleeding for patients with hemophilia A and B in a small study, Centessa said Thursday. In the trial, which enrolled just 23 people and was not placebo controlled, the highest dose of Centessa’s drug led to an 88% in annualized bleeding rate compared to baseline after six months.
Continue to STAT+ to read the full story…
